✦ LIBER ✦

Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes

✍ Scribed by Craig Cheetham; Julie Collis; Gerard O’Driscoll; Kim Stanton; Roger Taylor; Daniel Green

Book ID: 119541796
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 178 KB
Volume: 36
Category: Article
ISSN: 1558-3597
DOI: 10.1016/s0735-1097(00)00933-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improvement in endothelial function by a

Improvement in endothelial function by angiotensin-converting enzyme inhibition in non–insulin-dependent diabetes mellitus

✍ Gerard O’Driscoll; Daniel Green; Andrew Maiorana; Kim Stanton; Frances Colreavy; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Effect of an angiotensin II receptor ant

Effect of an angiotensin II receptor antagonist on endothelium-dependent, conduit vessel function in type 2 diabetes

✍ C. Cheetham; R.R. Taylor; W. Bilsborough; J.G. O'Driscoll; K. Stanton; D.J. Gree 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Short-term oral treatment with the angio

Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients

✍ Andreas Kjær; Ulrik Sloth Kristoffersen; Lise Tarnow; Hans-Henrik Parving; Birge 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 263 KB

Angiotensin II subtype-1 receptor antago

Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non–insulin-dependent diabetes mellitus

✍ Yoshio Uehara; Nobuhito Hirawa; Yukari Kawabata; Atsushi Numabe; Tomoko Gomi; To 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 314 KB

Effect of improved metabolic control on

Effect of improved metabolic control on loss of kidney function in Type 1 (insulin-dependent) diabetic patients: an update of the Steno studies

✍ B. Feldt-Rasmussen; E. R. Mathiesen; T. Jensen; T. Lauritzen; T. Deckert 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 867 KB

We re-examined 69 of the 70 patients entering the two independent Steno Studies of effects of improved metabolic control on progression of late diabetic complications. They were analysed according to an intent to treat after follow-up for 8 years (Steno Study 1) and 5 years (Steno Study 2). The glyc

Azilsartan, an angiotensin II type 1 rec

Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser1177/Thr497of endothelial nitric oxide synthase in diabetic mice

✍ Matsumoto, Sachiko; Shimabukuro, Michio; Fukuda, Daiju; Soeki, Takeshi; Yamakawa 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 373 KB